These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 39012079)
21. Activation of Wnt/β-catenin signaling promotes immune evasion via the β-catenin/IKZF1/CCL5 axis in hepatocellular carcinoma. Huang Y; Peng M; Yu W; Li H Int Immunopharmacol; 2024 Sep; 138():112534. PubMed ID: 38941667 [TBL] [Abstract][Full Text] [Related]
22. Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases. Zhou Z; Lei J; Fang J; Chen P; Zhou J; Wang H; Sun Z; Chen Y; Yin L Int Immunopharmacol; 2024 Sep; 139():112637. PubMed ID: 39033659 [TBL] [Abstract][Full Text] [Related]
23. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Homma S; Komita H; Sagawa Y; Ohno T; Toda G Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514 [TBL] [Abstract][Full Text] [Related]
24. Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity. Zhou S; Chen L; Qin J; Li R; Tao H; Zhen Z; Chen H; Chen G; Yang Y; Liu B; She Z; Zhong C; Liang C PLoS One; 2013; 8(9):e73952. PubMed ID: 24023916 [TBL] [Abstract][Full Text] [Related]
25. Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma. Chen Y; Zhang Y; Wang J; Cai X; Chen J; Min X; Xu Y; Qin Q; Wan C Int J Nanomedicine; 2024; 19():2227-2239. PubMed ID: 38465206 [TBL] [Abstract][Full Text] [Related]
26. The inducible effect of LBP on maturation of dendritic cells and the related immune signaling pathways in hepatocellular carcinoma (HCC). Chen JR; Li EQ; Dai CQ; Yu B; Wu XL; Huang CR; Chen XY Curr Drug Deliv; 2012 Jul; 9(4):414-20. PubMed ID: 22640039 [TBL] [Abstract][Full Text] [Related]
27. Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1. Park JH; Kim HY; Lee A; Seo YK; Kim IH; Park ET; Kang MS; Park SJ; Park S Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):510-520. PubMed ID: 33383126 [TBL] [Abstract][Full Text] [Related]
28. Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study. El-Ashmawy NE; El-Zamarany EA; Khedr EG; El-Bahrawy HA; El-Feky OA Clin Exp Med; 2018 Nov; 18(4):535-546. PubMed ID: 30062618 [TBL] [Abstract][Full Text] [Related]
29. [Inducing hepatocellular carcinoma-specific cytotoxic T lymphocyte response using formed by fusion of FastDCs and allogeneic human hepatocellular carcinoma cells]. Guan X; Leng XS; Peng JR; Wei YH; Wang H; Yuan L Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3332-6. PubMed ID: 16409838 [TBL] [Abstract][Full Text] [Related]
30. The expression and function of immunoglobulin-like transcript 4 in dendritic cells from patients with hepatocellular carcinoma. Fan J; Han J; Li J; Gu A; Yin D; Song F; Wang L; Yi Y Hum Immunol; 2020 Dec; 81(12):714-725. PubMed ID: 33228921 [TBL] [Abstract][Full Text] [Related]
32. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8 Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894 [TBL] [Abstract][Full Text] [Related]
33. In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances. Ishii R; Shimizu M; Nakagawa Y; Shimizu K; Tanaka S; Takahashi H Cancer Immunol Immunother; 2004 May; 53(5):383-90. PubMed ID: 14624311 [TBL] [Abstract][Full Text] [Related]
34. IL-12 improves the anti-HCC efficacy of dendritic cells loaded with exosomes from overexpressing Rab27a tumor cells. Li J; Lin W; Huang T; Chen M; Lin Q Exp Cell Res; 2024 Jun; 439(1):114073. PubMed ID: 38704079 [TBL] [Abstract][Full Text] [Related]
35. Dendritic cell-based vaccine targeting aspartate-β-hydroxylas represents a promising therapeutic strategy for HCC. Zhou Y; Li C; Shi G; Xu X; Luo X; Zhang Y; Fu J; Chen L; Zeng A Immunotherapy; 2019 Nov; 11(16):1399-1407. PubMed ID: 31608722 [No Abstract] [Full Text] [Related]
36. Tumor-derived microparticles in tumor immunology and immunotherapy. Ma J; Zhang H; Tang K; Huang B Eur J Immunol; 2020 Nov; 50(11):1653-1662. PubMed ID: 32976623 [TBL] [Abstract][Full Text] [Related]
37. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine. Shi W; Yang X; Xie S; Zhong D; Lin X; Ding Z; Duan S; Mo F; Liu A; Yin S; Jiang X; Xu ZPG; Lu X Cancer Lett; 2021 Dec; 522():184-197. PubMed ID: 34562519 [TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma. Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862 [TBL] [Abstract][Full Text] [Related]
39. Luteolin exerts anti-tumour immunity in hepatocellular carcinoma by accelerating CD8 Cai S; Gou Y; Chen Y; Hou X; Zhang J; Bi C; Gu P; Yang M; Zhang H; Zhong W; Yuan H J Cell Mol Med; 2024 Sep; 28(17):e18535. PubMed ID: 39267250 [TBL] [Abstract][Full Text] [Related]
40. Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate. Pan K; Zhao JJ; Wang H; Li JJ; Liang XT; Sun JC; Chen YB; Ma HQ; Liu Q; Xia JC Int J Biol Sci; 2010 Oct; 6(7):639-48. PubMed ID: 20975822 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]